부산대학교 도서관

Patients with primary refractory Hodgkin lymphoma (HL) or who relapse less than one year after completion of initial therapy will frequently respond to second line therapy. A majority of those who have a complete response (CR) to salvage therapy, and are then consolidated with high-dose chemotherapy and autologous stem cell rescue will experience prolonged relapse-free survival. It is therefore critical to identify those patients who are unlikely to respond to a given salvage regimen, so they can be given alternate treatment.